AlgoHunter Logo

AlgoHunter - Stock Profile

Login

IMTX

$10.23

$

Biotechnology

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Next Earnings

2026-02-25

Beta

1.361

Average Volume

Market Cap

Last Dividend

CIK

0001809196

ISIN

NL0015285941

CUSIP

N44445109

CEO

Harpreet Singh

Sector

Healthcare

Industry

Biotechnology

Full Time Employees

554

IPO Date

2018-12-12

Status

Active

Latest News

Title Headline Publisher Date
Immatics (NASDAQ:IMTX) Trading Down 5% – Here’s What Happened Immatics N.V. (NASDAQ: IMTX - Get Free Report)'s share price traded down 5% on Friday. The stock traded as low as $9.95 and last traded at $9.79. 25,593 shares were traded during trading, a decline of 93% from the average session volume of 381,668 shares. The stock had previously closed at $10.30. Wall Street Analysts Defense World 2026-02-22 04:36:54
Immatics N.V. (NASDAQ:IMTX) Receives Average Recommendation of “Moderate Buy” from Analysts Shares of Immatics N.V. (NASDAQ: IMTX - Get Free Report) have been given an average recommendation of "Moderate Buy" by the eight research firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to Defense World 2026-02-02 04:09:00
Immatics (NASDAQ:IMTX) Stock Price Up 3.9% – Should You Buy? Immatics N.V. (NASDAQ: IMTX - Get Free Report) shot up 3.9% on Wednesday. The stock traded as high as $10.42 and last traded at $10.4630. 130,449 shares traded hands during mid-day trading, a decline of 83% from the average session volume of 764,094 shares. The stock had previously closed at $10.07. Wall Street Analyst Weigh Defense World 2026-01-02 03:38:50
Immatics: PRAME Leader's Transition To Commercial Reality Immatics executes a three-wave strategy, progressing from melanoma treatment to broader solid tumors and scalable bispecific TCR therapeutics. IMTX's $505.8M cash position funds operations through 2027, covering BLA submission and anticipated commercial launch, reducing near-term financing risk. Anzu-cel's Phase 3 SUPRAME trial and IMA203CD8's promising ovarian cancer data support a robust, expanding clinical pipeline with significant addressable markets. Seeking Alpha 2025-12-25 00:04:55
Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress Houston , Texas and Tuebingen, Germany, December 11, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, today announced updated Phase 1a dose escalation data from its second-generation PRAME cell therapy, IMA203CD8, in heavily pre-treated patients with solid tumors. Based on the enhanced pharmacology of IMA203CD8 reported previously, IMA203CD8 provides the potential to address difficult-to-treat solid tumors expressing PRAME beyond melanoma, such as ovarian cancer. GlobeNewsWire 2025-12-11 07:00:00
Immatics Announces $125 Million Underwritten Offering Houston, Texas and Tuebingen, Germany,  December 05, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, announced today that it has agreed to sell 12,500,000 ordinary shares at $10.00 per share in an underwritten offering. The gross proceeds from the offering, before deducting the underwriting discount and offering expenses, are expected to be $125 million. The offering is expected to close on December 8, 2025, subject to customary closing conditions. GlobeNewsWire 2025-12-05 06:00:00
Immatics (NASDAQ:IMTX) Sets New 12-Month High – Here’s What Happened Immatics N.V. (NASDAQ: IMTX - Get Free Report)'s share price hit a new 52-week high on Friday. The stock traded as high as $12.41 and last traded at $11.87, with a volume of 1011398 shares. The stock had previously closed at $10.34. Wall Street Analyst Weigh In IMTX has been the subject of a number Defense World 2025-12-05 04:14:51

SEC Filings

Type Filing Date Accepted Date Link
SC 13G/A 2026-02-17 2026-02-17 View Filing
SC 13G/A 2026-02-13 2026-02-13 View Filing
6-K 2026-01-12 2026-01-12 View Filing
6-K 2025-12-11 2025-12-11 View Filing
6-K 2025-12-08 2025-12-08 View Filing
424B5 2025-12-05 2025-12-05 View Filing
424B5 2025-12-05 2025-12-04 View Filing
6-K 2025-11-17 2025-11-17 View Filing
SC 13G/A 2025-11-14 2025-11-14 View Filing
SC 13G/A 2025-11-14 2025-11-14 View Filing
6-K 2025-11-12 2025-11-12 View Filing
6-K 2025-10-27 2025-10-27 View Filing
6-K 2025-10-01 2025-10-01 View Filing
SC 13G/A 2025-08-14 2025-08-14 View Filing
SC 13G/A 2025-08-14 2025-08-14 View Filing
SC 13G/A 2025-08-13 2025-08-13 View Filing
6-K 2025-08-13 2025-08-13 View Filing
SC 13G/A 2025-08-12 2025-08-12 View Filing
S-8 2025-07-02 2025-07-01 View Filing
25-NSE 2025-07-01 2025-06-30 View Filing
6-K 2025-06-18 2025-06-18 View Filing
6-K 2025-06-02 2025-06-02 View Filing
6-K 2025-06-02 2025-06-02 View Filing
6-K 2025-05-13 2025-05-13 View Filing
SC 13G/A 2025-05-12 2025-05-12 View Filing
SC 13G/A 2025-05-02 2025-05-02 View Filing
EFFECT 2025-04-04 2025-04-04 View Filing
F-3 2025-03-27 2025-03-27 View Filing
6-K 2025-03-27 2025-03-27 View Filing
20-F 2025-03-27 2025-03-27 View Filing
SC 13G/A 2025-03-07 2025-03-07 View Filing
SC 13G/A 2025-02-14 2025-02-14 View Filing
SC 13G 2025-02-14 2025-02-14 View Filing
SC 13G/A 2025-02-14 2025-02-14 View Filing
SC 13G/A 2025-02-14 2025-02-14 View Filing
SC 13G 2025-02-11 2025-02-11 View Filing
6-K 2025-01-13 2025-01-13 View Filing
6-K 2024-12-13 2024-12-13 View Filing
6-K 2024-11-18 2024-11-18 View Filing
SC 13G 2024-11-14 2024-11-14 View Filing
SC 13G 2024-11-14 2024-11-14 View Filing
6-K 2024-11-08 2024-11-08 View Filing
SC 13G/A 2024-11-08 2024-11-08 View Filing
SC 13D/A 2024-10-17 2024-10-17 View Filing
6-K 2024-10-15 2024-10-15 View Filing
424B2 2024-10-11 2024-10-11 View Filing
424B2 2024-10-10 2024-10-10 View Filing
F-3ASR 2024-10-10 2024-10-10 View Filing
6-K 2024-10-10 2024-10-10 View Filing
6-K 2024-09-16 2024-09-16 View Filing
6-K 2024-08-13 2024-08-13 View Filing
6-K 2024-07-31 2024-07-31 View Filing
S-8 2024-07-22 2024-07-22 View Filing
6-K 2024-06-20 2024-06-20 View Filing
SC 13D 2024-06-06 2024-06-06 View Filing
SC 13G/A 2024-06-06 2024-06-06 View Filing
6-K 2024-06-03 2024-06-03 View Filing
6-K 2024-05-14 2024-05-14 View Filing
6-K 2024-03-21 2024-03-21 View Filing
20-F 2024-03-21 2024-03-21 View Filing

Algorithm Performance

Upgrade To Premium for Full Access
Algorithm Profit/Loss Profit Factor # Trades Sharpe Sortino Efficiency
Pivot Points Strategy 41.60% 0.9 13 0.68 1.07 27.86
Bull Bias 39.88% 0.98 39 0.48 0.52 26.14
Hull Moving Average Strategy 37.06% 0.97 38 0.48 0.54 23.32
xxxxxxxxxxxxx xxxxxxx% xxxx x xxxx xxxx xxxxx
xxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxx% xxxx xx xxx xxxx xxxxx
xxxxxxxxxxxxxxxxxxxxx xxxxxxx% xxxx x xxxx xxxx xxxxx
xxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxx% xxxx xx xxx xxxx xxxx
xxxxxxxxxxxxxxxxxxxxxxxx xxxxxxx% x x xxx x xxxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxx% x x xxx x xxxxx
xxxxxxxxxxxxxxxxxxxxxx xxxxxxx% xxxx xx xxx xxxx xxx
xxxxxxxxxxxxxxxxxxxxxxxxxx xxxxx% xxxx xx xxxx xxxx xxxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxx% xxxx xx xxxx xxxx x
xxxxxxxxxx xxxxxxx% xxxx xx xxxx xxxx xxxxx
xxxxxxxxxxxxx xxxxxxx% xxxx xx xxxx xxxx x
xxxxxxxxxxxxxxxxx xxxxxxx% xxxx xx xxxx xxxx xxxx
xxxxxxxxxxxxxx xxxxxxx% xxxx xx xxxx xxxx xxxx
xxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxx% xxxx xx xxx xxxx xxxx
xxxxxxxxxxxxxxxxxxxxxxxx xxxxxxx% xxxx x xxxx xxxx xxxx
xxxxxxxxxxxxxxxxxxxxxxx xxxxxxx% x x xxxx xxxx xxxx
xxxxxxxxxxxxxxxxxxxx xxxxxx% xxxx xx xxxx xxxx xxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxx% x xx xxxx xxxx xxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxx% xxxx xx xxxx xxxx xxxx
xxxxxxxxxxxxxxxxxxxxxxx xxxxxxx% xxxx x xxxx xxxx xxxx
xxxxxxxxxxxxxx xxxxxxx% xxxx xx xxxx xxxx xxxx
xxxxxxxxx xxxxxxx% xxxx xx xxxx xxxx xxxx
xxxxxxxxxxxxxxxxxxxxxxxxx xxxxxx% x xx xxxx xxxx xxxx
xxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxx% x xx xxxx xxxx xxxx
xxxxxxxxxxxx xxxxxxx% x x xxxx xxxx xxxx
xxxx xxxxxxx% x xx xxxx xxxx xxxxx
xxxxxxxxxxxxxxxxxxxx xxxxxxx% x xx xxxx xxxx xxxx
xxxxxxxxx xxxxxxx% x xx xxxx xxx xxxx
xxxxxxxxxxxxxxxxxxxx xxxxxxx% xxxx xx xxx xxxx xxxx
xxxxxxxxxxxxxxxxxxxx xxxxxxx% xxxx x xxxx xxxx xxxx
xxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxx% xxxx xx xxxx xxxx xxx
xxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxx% x xx xxxx xxxx xxxx
xxxxxxxxxx xxxxxxx% xxxx xx xxxx xxxx xxx
xxxxxxxxxxxxxxxxxxxx xxxxxxx% xxxx x xxxx xxxx xxxx
xxxxxxxxxxxxxx xxxxxxx% xxx xx xxxx xxxx xxxxx
xxxxxxxxxxxxxxxxxxxxxxxx xxxxxxx% xxxx xx xxxx xxxx xxxx
xxxxxxxxxxxxxxxxxxxx xxxxxxx% x xx xxxx xxxx xxxxx
xxxxxxxxxxxxxxxxxxxxxxx xxxxxxx% xxxx x xxxx x x
xxxxxxxxxxxxxxxxxxxxxxxx xxxxxx% xxxx x xxxx xxxx xxx
xxxxxxxxx xxxxxxx% xxxx x xxxx xxxx xxxxx
xxxxxxxxxxxxxxxxxxxxxx xxxxxxx% xxx xx xxxx xxxx xxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxx% xxxx xx xxxx xxxx xxxx
xxxxxxxxxx xxxxxx% xxxx xx xxxx xxxx xxxx
xxxxxxxxxxxxx xxxxxx% xxxx xx xxxx xxxx x
xxxxxxxxxxxx xxxxxx% xxxx x xxxx x xxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxx% xxxx x xxxx xxx xxxx
xxxxxxxxxxxxxxxxxxxxxxxxx xxxxxx% xxxx xx xxxx xxxx xxxx
xxxxxxxxxxxxxxxxx xxxxxx% xxxx xx xxxx xxxx xxx
xxxxxxxxxxxx xxxxxx% xxxx x xxxx xxxx xxx
xxxxxxxxxxxxxxxxxxxxxxx xxxxxx% x x xxxx xxxx xxx
xxxxxxxxxxxxxxxxxxxxx xxxxxx% xxxx xx xxxxx xxxx xxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx x% x xx x x xxxx
xxxxxxxxxxxxxxxxxxxxxxx x% x xx x x xxxxx
xxxxxxxxxxxxxxxxxxxxxxx x% x xx x x xxx
xxxxxxxxxxxxxxxxxxxxx x% x xx x x xxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx x% x xx x x xxxx
xxxxxxxxxxxxxxxxxxxxxxxx x% x xx x x xxxxx
xxxxxxxxxx x% x xx x x xxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx x% x xx x x xxxx
xxxxxxxxxxxxx x% x xx x x xxx
xxxxxxxxx x% x xx x x xxx
xxxxxxxxxxxxxxxxxxxxxxx x% x xx x x xxxx
xxxxxxxxxxxxxxxxxxxxxxx x% x x x x xxx
xxxxxxxxxxxxxxxxxxxxxxxx x% x xx x x xxx
xxxxxxxxxxxxxxxxxx x% x x x x xxxx
xxxx x% x xx x x xxxx
xxxxxxxxxxxxxxxxxxxxxxx x% x xx x x xxxxx
xxxxxxxxxxxxxxxxxxxxx x% x x x x xxxx
xxxxxxxxxxxxxxxxxxxxxxxx x% x xx x x xxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx x% x x x x xxxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx x% x xx x x xxx
xxxxxxxxxxxxxxxxxxxxxxx x% x xx x x xxxx
xxxxxxxxxxxxxxxxxxxxx x% x x x x xxxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx x% x xx x x xxxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx x% x x x x xxx
xxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxx% x xx xxxxx x xxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxx% xxxx xx xxxxx x xxxx
xxxx xxxxxxx% x xx xxxxx xxxxx xxxx
xxxxxxxxxx xxxxxxx% xxxx xx xxxxx xxxxx xxxx
xxxxxxxxxxxxx xxxxxxx% xxxx xx xxxxx xxxxx x
xxxxxxxxxxxx xxxxxxx% x x xxxxx xxxxxx xxxxx
xxxxxxxxx xxxxxxx% x xx xxxxx xxxxx xxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxx% x xx xxxxx xxxxx xxxx
xxxxxxxxx xxxxxxx% xxxx xx xxxxx xxxxx xxxx
xxxx xxxxxxx% xxxx xx xxxx xxxxx xxxx
xxxxxxxxxxxxxxxxxxxxxxxxx xxxxxx% x xx xxxxx xxxxx xxxx
xxxxxxxxxxxxxxxxx xxxxxxx% xxxx xx xxxxx xxxxx xxxx
xxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxx% xxxx xx xxxxx xxxxx xxxx
xxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx% x xx xxxxx xxxxx xxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx% xxx xx xxxxx xxxxx xxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx% xxxx xx xxxxx xxxx xxxx
xxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx% xxxx x xxxxx xxxxx xxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx% x xx xxxxx xxxxx xxxx
xxxxxxxxxxxxxxxxx xxxxxxxx% xxxx xx xxxxx xxxxx xxxx
xxxxxxxxxxxxxxxxxxxxx xxxxxxxx% x xx xxxx xxxxx xxxx
xxxxxxxxxxxxxx xxxxxxxx% xxxx xx xxxxx xxxxx xxxx
xxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx% x xx xxxxx xxxxx xxxx
xxxxxxxxx xxxxxxxx% xxxx xx xxxxx xxxxx xxxx
xxxxxxxxxxxxx xxxxxxxx% xxxx x xxxxx xxxxx xxxx
xxxxxxxxx xxxxxxxx% xxxx xx xxxx xxxxx xxxx
xxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx% xxxx xx xxxxx xxxxx xxxx
xxxxxxxxx xxxxxxx% xxxx x xxxxx xxx xxxx
xxxxxxxxx xxxxxxxx% xxxx xx xxxx xxxxx xxxx
xxxx xxxxxxxx% xxxx xx xxxxx xxxxx xxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx% xxxx xx xxxxx xxxx xxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx% xxxx x xxxx xxxxx xxxx
xxxxxxxxxxxxxxxxxxxxx xxxxxxxx% xxxx x xxxxx xxxxxx xxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx% x xx xxxxx xxxxx xxxxx
xxxxxxxxx xxxxxxxx% xxxx xx xxxxx xxxxx xxxx
xxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx% xxxx xx xxxxx xxxxx xxxxx
xxxxxxxxxxxxxxxxxx xxxxxxx% x x xxxx xxxxx xxxx
xxxxxxxxxxxxxxxxxxxxxx xxxxxxxx% x xx xxxxx xxxxx xxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx% x xx xxxxx xxxxx xxxx
xxxxxxxxx xxxxxxxx% xxxx x xxxxx xxxxx xxxx
xxxx xxxxxxxx% xxxx xx xxxxx xxxxx xxxx
xxxxxxxxxx xxxxxxxx% xxxx xx xxxx xxxxx xxxx
xxxxxxxxxxxxxxxxxxxxxxxx xxxxxxx% x x xxxxx xxxxx xxx
xxxxxxxxxxxxxxxxxxxxx xxxxxxx% x x xxxxx xxxxx xxx
xxxx xxxxxxxx% xxx xx xxxxx xxxxx xxxx
xxxxxxxxxxxxxxxxxxxxxx xxxxxxxx% xxxx xx xxxxx xxxxx xxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx% xxxx xx xxxxx xxxxx xxxx
xxxxxxxxxxxxxxxxxxxxx xxxxxxxx% xxxx x xxxx xxxxx xxxx
xxxx xxxxx% xxxx xx xxxxx xxxxx xxxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx% xxxx xx xxxxx xxxxx xxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx% xxxx xx xxxxx xxxxx xxxx
xxxxxxxxxxxxxxxxxxxx xxxxxxxx% xxxx xx xxxxx xxxxx xxxx
xxx xxxxxxxx% xxxx xx xxxxx xxxxx xxxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx% xxxx xx xxxxx xxxxx xxxxx
xxxxxxxxxxxxx xxxxxxxx% xxxx x xxxxx xxxxx xxxx
xxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx% xxxx xx xxxxx xxxxx xxxxx
xxxxxxxxxx xxxxxxxx% xxxx xx xxxxx xxxxx xxxxx
xxxxxxxxxxxxxxxxxxxxx xxxxxxxx% xxxx xx xxxxx xxxxx xxxxx
xxxxxxxxxxxxx xxxxxx% xxxx x xxxxx xxxxx xxxxx
xxxxxxxxxxxxxxxxxxxx xxxxxxxx% xxxx xx xxxxx xxxxx xxxxx
xxxxxxxxxxxxxxxxxx xxxxxxxx% x x xxxxx xxxxx xxxxx
xxxxxxxxxx xxxxxxxx% xxxx xx xxxx xxxxx xxxxx